Results 71 to 80 of about 16,167 (200)

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives [PDF]

, 2016
Bertram Pitt, João Pedro Ferreira, Faı̈ez Zannad   +2 more
openalex   +1 more source

How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?

Journal of the Formosan Medical Association
Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that,
Jin-Ying Lu, Yi-Yao Chang, Ting-Wei Lee, Ming-Hsien Wu, Zheng-Wei Chen, Yen-Ta Huang, Tai-Shuan Lai, Leay Kiaw Er, Yen-Hung Lin, Vin-Cent Wu, Hao-Min Cheng, Hsien-Li Kao, Charles Jia-Yin Hou, Kwan-Dun Wu, Szu-Tah Chen, Feng-Hsuan Liu   +15 more
doaj   +1 more source

Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure [PDF]

, 2019
Neven Sarhan, Mohamed H. Shahin, Nihal M. El Rouby, Lamia El Wakeel, Mohamed H. Solayman, Taimour Langaee, Hazem Khorshid, Mona F. Schaalan, Nagwa A. Sabri, Larisa H. Cavallari   +9 more
openalex   +1 more source

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD

, 2021
Murray Epstein, Roberto Pecoits‐Filho, Catherine M. Clase, Manish M. Sood, Csaba P. Kövesdy   +4 more
openalex   +2 more sources

Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists

, 2013
Kentaro Futatsugi, David W. Piotrowski, Agustin Casimiro‐Garcia, Shaughn Robinson, M. F. Sammons, Paula M. Loria, Mary Ellen Banker, Donna N. Petersen, Natalia J. Schmidt   +8 more
openalex   +1 more source

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

, 2020
Tadakatsu Nakamura, H. Shimizu, Atsuhiro Kawaguchi   +2 more
openalex   +1 more source

Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden.
Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Wenbin Gao, Austin Todd, Joseph J. Maleszewski, Francis D. Pagani, Hartzell Schaff, Y. Eugene Chen, Paul A. Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C. Tang   +18 more
doaj   +1 more source

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

Integrated Blood Pressure Control, 2013
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone was shown to be an extraordinarily effective ...
openaire   +4 more sources

Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach? [PDF]

, 2017
João Pedro Ferreira, Robert J. Mentz, Anne Pizard, Bertram Pitt, Faı̈ez Zannad   +4 more
openalex   +1 more source

Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes

, 2022
Edgar V. Lerma, Daniel J. Wilson
openalex   +1 more source